MiR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma

Richard Flavin*, Paul Smyth, Ciara Barrett, S. Russell, Hannah Wen, Jian-Jun Wei, Alex Laios, Sharon O'Toole, M. Ring, K. Denning, J. Li, S. Aherne, D. Sammarae, N. A. Aziz, A. Alhadi, Sephen P. Finn, M. Loda, B. Sheppard, Orla Sheils, John J. O'Leary

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

51 Scopus citations

Abstract

Micro-RNAs are a group of small noncoding RNAs approximately 22 nucleotides in length. Recent work has shown differential expression of mature micro-RNAs in human cancers. We characterized the alteration in expression of miR-29b in ovarian serous carcinoma. miR-29b expression was analyzed using quantitative stem-loop reverse transcriptase polymerase chain reaction on a set of 50 formalin-fixed, paraffin-embedded ovarian serous carcinoma samples. Protein expression of p53, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67, and insulinlike growth factor 1 was quantified in the corresponding tissue microarray. The expression profile of miR-29b was correlated with clinicopathological and patient survival data. We provide definitive evidence that miR-29b is down-regulated in a significant proportion of ovarian serous carcinomas and is associated with specific clinicopathological features, most notably high miR-29b expression being associated with reduced disease-free survival.

Original languageEnglish (US)
Pages (from-to)641-647
Number of pages7
JournalInternational Journal of Gynecological Cancer
Volume19
Issue number4
DOIs
StatePublished - May 1 2009

Keywords

  • Biomarkers
  • Micro-RNA
  • Ovarian serous carcinoma

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'MiR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma'. Together they form a unique fingerprint.

Cite this